Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

PurposePatients with advanced/relapsed rare cancers have few treatment options. Analysis of circulating tumor DNA in plasma may identify actionable genomic biomarkers using a non-invasive approach.Patients and MethodsRare cancer patients underwent prospective plasma-based NGS testing. Tissue NGS to...

Full description

Bibliographic Details
Main Authors: Hitomi Sumiyoshi Okuma, Kan Yonemori, Yuki Kojima, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Susumu Hijioka, Keiko Wakakuwa, Ken Kato, Akihiro Hirakawa, Aya Kuchiba, Takashi Kubo, Hitoshi Ichikawa, Akihiko Yoshida, Yasushi Yatabe, Kenichi Nakamura, Hiroyuki Mano, Noboru Yamamoto, Yasuhiro Fujiwara
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
rare cancer
CtDNA (circulating tumor DNA)
precision medicine
soft tissue sarcoma
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.732525/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.732525/full

Similar Items